Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Author(s): Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
Issue: Jul/Aug 2021 - Volume 25, Number 4
View All Articles in Issue
Page(s): 336-343
Download in electronic PDF format for $75
Abstract: In this work, we focus on three ready-to-use vehicles: Fitalite, Versatile, and HRT Supreme Cream Base. Fitalite is a natural, light, hydrophilic gel-cream that contains vitamin E and oil bodies from plant sources (phytosomes), providing antioxidant and skinmoisturizing properties. Versatile is a vanishing oil-inwater cream base which retains its consistency with a broad range and high concentrations of active pharmaceutical ingredients, dermaceutical ingredients, and solvents. Finally, HRT Supreme Cream Base is a paraben-free, dye-free, fragrance-free O/W emulsion base, formulated with a complex of botanical oils to soothe and provide moisture to dry and sensitive skin. In the current study, we evaluated the beyond-use date of formulations containing estradiol, estriol, estrone, progesterone, and testosterone in combination, compounded with these three vehicles. Validated, stability-indicating high-performance liquid chromatography methods were used throughout a 180-day period. A beyond-use date of 180 days was observed for all vehicles stored both at refrigerated and at room temperature. The combination of five ingredients represents a worst-case scenario since there are more possibilities of cross reactions. Therefore, we expect the same or greater stability as individual ingredients are removed from the tested formulation. The extended beyond-use dates provide convenience for both the compounding pharmacist and the patient.
Related Keywords:
commercial vehicles, estradiol, estriol, estrone, progesterone, testosterone, hormone replacement therapy, topical preparations, transdermal application, emulsions, Fitalite gel-cream, Versatile vanishing o/w cream base, HRT Supreme Cream base, drug combinations, compatibility, chemical stability, physical stability
Related Categories:
EXCIPIENTS, HRT, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
|
Jul/Aug 2021
Pg. 336-343
|
Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases
Allen Loyd V Jr
|
May/Jun 2017
Pg. 238
|
Estradiol 0.25 mg/g, Estrone 0.25 mg/g, and Estriol 2 mg/g in HRT Cream Base
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 407
|
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Ford Gina, Garcia Lea
|
Jan/Feb 2001
Pg. 52-54
|
Estriol 2-mg/mL, Estrone 0.25-mg/mL, and Estradiol 0.25-mg/mL Topical Solution
Allen Loyd V Jr
|
Jul/Aug 2002
Pg. 298
|
Bioidentical Hormone Replacement Therapy, Part 3, A Review of
Wepfer Scott T
|
Mar/Apr 2002
Pg. 142-146
|
Estriol and Estradiol 2.5-mg, Progesterone 50-mg, and Testosterone 1-mg Capsules
Allen Loyd V Jr
|
Nov/Dec 2000
Pg. 458
|
Saliva Tests, Part 2: Salivary Hormones, Hormone Replacement Pharmacokinetics, and the Importance of Timely Testing
Kells John, Dollbaum Charles M
|
Sep/Oct 2009
Pg. 392-399
|
Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Jan/Feb 2015
Pg. 6-12
|
Stability of Fagron's Phytobase Cream Compounded with Various Hormones
Wynn Tom, Taylor Sarah, Zander Clark
|
Mar/Apr 2021
Pg. 156-162
|
Bilateral Areolar Hyperpigmentation Following Transdermal Administration of Compounded Hormone Replacement Therapy
Griffee Chris, Delano Amy
|
Mar/Apr 2012
Pg. 110-114
|
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Gillson George R, Zava David T
|
Jul/Aug 2003
Pg. 250-256
|
Establishing a Rationale for Compounding Hormone Replacement Therapy
Biundo Bruce
|
May/Jun 2018
Pg. 190-195
|
Establishing a Rationale for Compounding Hormone Replacement Therapy
Biundo Bruce
|
Jan/Feb 2024
Pg. 22-27
|
Basics of Compounding with Dilutions and Concentrates
Allen Loyd V Jr
|
Jan/Feb 2017
Pg. 39-45
|
Bioidentical Hormone Replacement Therapy, Part 2, A Review of
Wepfer Scott T
|
Jan/Feb 2002
Pg. 50-54
|
Progesterone-Estradiol-Testosterone in Oil Capsules
Allen Loyd V Jr
|
Jan/Feb 1998
Pg. 54
|
Progesterone 10% Cream
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 412
|
Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn, Needham Shane
|
Nov/Dec 2018
Pg. 466-468
|
Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Glaser Rebecca L, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
|
Jul/Aug 2009
Pg. 314-317
|
Return to Top |